Neumentum, Inc.

HERZLIYA, Israel and CALGARY, Alberta, Dec. 12, 2023 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce establishment of a specialized team to prepare the Company's submission to the United States Food and Drug Administration (the "FDA") for the human application of its LPT CBD platform. The team is comprised of accomplished drug development and drug approval experts, with specific a experience in pharmacology, toxicology, clinical trials, and successful interaction with the FDA. Dr. Robert B. Raffa, PhD, is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy. He was a Research Fellow and a Team Co-Leader for analgesics drug discovery at Johnson & Johnson Inc., where he was pivotal in the elucidation of the mechanism of action and development of the analgesic drug tramadol (Ultram™). He is a Co-Founder and the Vice President of Biology of CaRafe Drug Innovation LLC, a Co-Founder and member of the Scientific Advisory Board at Enalare Therapeutics Inc., the Chief Scientific Officer of Neumentum Inc., and Chairman of the Scientific Advisory Board at Advantx Pharmaceuticals Inc. He is the co-holder of several patents, has published more than 400 papers in scientific journals, has co-authored or edited several books on pharmacology and thermodynamics, and is the recipient of research and teaching awards. He lectures and consults worldwide on the pharmacology of drug development. Dr. Kory J. Engelke, PhD, DABT, brings more than 26 years of drug development/regulatory experience. He is experienced pharmacologist and board-certified toxicologist with demonstrated proficiency in the design, implementation, interpretation, reporting, and defense of nonclinical and clinical studies and strategies to worldwide regulatory bodies and potential business partners. Dr. Engelke has held several different scientific roles within the drug development industry including study director, study sponsor and consultant and will be serving as a toxicology consultant to the Company. Dr. Engelke has published more than a dozen publications relating to drug development in pharmacology and toxicology. Dr. Joseph V. Pergolizzi Jr., MD, is the Co-Founder and Chief Operating Officer of NEMA Research Inc. and a Senior Partner at Naples Anesthesia and Pain Associates, Inc. Dr. Pergolizzi is an internationally renowned perioperative and pain specialist, well-versed in the multiplicity of issues confronting patients and caregivers in acute and chronic pain. Dr. Pergolizzi has leveraged his significant medical, regulatory, and business expertise to build a strong track record of success within the healthcare industry. Previously, Dr. Pergolizzi served as an adjunct part-time assistant professor in the Department of Medicine at Johns Hopkins University School of Medicine, a committee member of the FDA's Safe Use Initiative and as a Special Government Employee for the Veterans Health Administration. Dr. Pergolizzi is the author of more than 350 peer reviewed articles, abstracts, platform presentations and book chapters, and has been awarded the American Medical Association Physician Recognition Award with Commendation. Innocan CEO, Iris Bincovich, stated: "At Innocan, we continue to develop our liposomal CBD platform to play a role in effectively combating various diseases in the future. That's why we have put together an experienced team to guide us through the FDA approval process. We are excited to work with such leading experts to help Innocan Pharma achieve our gools and move the company forward with the FDA." About Innocan Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. For further information, please contact: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding the filing of potential applications with the FDA for the human application of the Company's LPT CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo: SOURCE Innocan Pharma Corporation

All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all HNVs in the Phase I clinical study of its novel Ketorolac for IV infusion (NTM-001), a non-opioid analgesic drug co-developed with Neumentum. A total of 16 healthy normal volunteers (HNVs) were recruited for the Phase I clinical study. All subjects had completed sample collections up to 96 hours and passed a 15-day safety follow-up period. To date, there have been no serious adverse events or alarming safety concerns reported among any of the subjects. According to Nuance R&D head, sample data clean-up and statistical analysis are in progress. The Phase I clinical study is estimated to be completed later this year. In late 2020, Nuance Pharma entered into an exclusive license agreement with Neumentum for the rights to develop and commercialize the novel intravenous infusion of ketorolac (NTM-001) in Greater China. The asset is currently in Phase III development in the U.S. for the short-term management of moderately severe pain. "It gives me great pleasure to announce the smooth completion of Phase I dosing for NTM-001 in Hong Kong. This represents a crucial milestone for our collaboration with Neumentum and is indicative of a grand opening to the China clinical development program. NTM-001 provides injectable non-opioid analgesic to patients and will be a promising alternative candidate for the use of opioid drugs in analgesics," commented Mark G. Lotter, CEO and Co-Founder of Nuance Pharma. "We are looking forward to introducing this novel drug in Greater China to address unmet needs in the pain management market." "We are very excited to have completed this important study for NTM-001, further demonstrating the safety of the compound," stated Joseph Pergolizzi MD, Executive Chairman of Neumentum. " We believe NTM-001 has the potential to significantly improve the standard of care for many patients experiencing moderately severe, acute pain requiring analgesia at the opioid level. We believe the results of this study further highlight the profile of NTM-001 as a potentially effective and safe short-term pain management solution and provide valuable information for the product's clinical program moving forward." About Ketorolac (NTM-001) Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia at the opioid level, usually in a postoperative setting with the potential benefit of consistent pain relief without the risks associated with opioids, or the disadvantages of bolus short-acting analgesics. About Pain in Postoperative Period (POP) In 2020, there was an estimated 66 million inpatient surgical operations in Chinese hospitals. 1) There is significant demand for pain management in the POP setting in China, driven by the huge inpatient surgery volume and double-digit growth rates. 2) In the POP setting, the main goal of pain management is to reduce pain or discomfort to the extent possible and minimize side effects at the same time. However, despite medical advancements in the last decades, opioids remain the backbone of POP pain management in the moderate to severe setting despite the serious side-effects. There is substantial need for a non-opioid pain management option that affords consistent, opioid-level pain relief that is, at the same time, safe to address the significant unmet medical needs in China's pain management market. About Nuance Pharma Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance's portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care and iron deficiency anemia. Focusing on specialty care, Nuance deploys the Dual Wheel model that incubates a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation. About Neumentum Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management, without the risks for abuse, misuse and diversion seen with opioids or the opioid-induced side effects, including potentially life-threatening respiratory depression. Neumentum is led by an experienced executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit . Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contacts: Nuance Pharma Vicky Lin, IR & PR Senior Manager, [email protected], Tel: +86 21 3203 5318 Neumentum Inc. Melissa Donnelly, Public Relations Manager, [email protected] Tel: +1 (833) 638-7246 SOURCE Nuance Pharma Limited

MORRISTOWN, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will present at two upcoming investor conferences in January. About Neumentum: Addressing a National Health Emergency Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the risks of abuse, misuse and diversion seen with opioids, or opioid-induced side effects including potentially life-threatening respiratory depression. Opioid use is considered a critical public health concern in the US. In 2018, 9.9 million people over age of 12 reported misusing prescription opioid pain relievers1, and opioids were involved in 46,802 overdose deaths.2 Opioids also account for over 305,000 emergency department visits annually for non-fatal overdoses.3 Despite these staggering statistics, and the frequently reported opioid-induced side effects such as nausea, vomiting, constipation and somnolence, 168 million prescriptions – over 51 prescriptions per 100 Americans – were written for opioids in 2018.4 Neumentum has two lead product candidates being developed to directly help address the opioid crisis. NTM-006, a Phase 2 novel oral analgesic with a target indication for moderate to severe chronic pain, was licensed in late 2019. NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac), with recent Phase I results showing that it may provide consistent, steady blood plasma levels of ketorolac over 24 hours and durable analgesic effect. This Phase I study is part of a program supporting what has the potential to be the first-ever NSAID approved for continuous infusion. Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit . INVESTOR CONTACT: Scott ShivelyCEO & Co-founderscottshively@neumentum.com (833) NEUPAIN MEDIA CONTACT:Megan KernanWestwicke, an ICR companymegan.kernan@westwicke.com(952) 221-2096 ______________________ [1] SAMSHA, Key Substance Use and Mental Health Indicators in the US: Results from the 2018 National Survey on Drug Use and Health. P13, Fig 10.[2] Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL. MMWR Morb Mortal Wkly Rep 2020; 69:290–297[3] Vivolo-Kantor AM, Hoots BE, Scholl L, et al. MMWR Morb Mortal Wkly Rep 2020;69:371–376[4] , accessed 16 Jul 2020